After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial.

A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of 'good' cholesterol, ...

After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial ...

CLEVELAND — Fenofibrate, patented in 1969 and in medical use since 1975, is well-established as a cholesterol-lowering treatment. However, University Hospitals scientists believe it may also have the ...

Objective: In order to assess the long-term (12 months) efficacy and safety of fenofibrate administered with simvastatin in the treatment of primary mixed hyperlipidaemia, we conducted a study that ...

(HealthDay)—A combination of testosterone and fenofibrate may offer men with high cholesterol and late-onset hypogonadism the most cardiometabolic benefit, according to a study published online May 29 ...

Given that PPARα is the molecular target for fenofibrate and its known, albeit incompletely understood, roles in lipid metabolism and inflammation, we investigated whether genetic variation in the ...

Use of the cholesterol-lowering drug fenofibrate had a modest but statistically significant association with reduced risk of vision-threatening diabetic retinopathy (VTDR), according to results of a ...

Fenofibrate, an FDA-approved drug used to reduce cholesterol levels, causes sensory neurons in the spine following spinal cord injury to regrow twice as fast as with a placebo treatment. The results ...

To investigate the metabolite changes caused by simvastatin or fenofibrate intervention in diet-induced hyperlipidemia rats using a GC-MS-based metabolomic profiling approach. Oral administration of ...

PHILADELPHIA—After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized ...